stockrowAbeona Therapeutics Inc.
ABEOAbeona Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.8 million, up 66.3% from fiscal 2023.
- Revenue
- +225.1%
- EPS
- −116.9%
- Free cash flow
- +17.1%
- Total debt
- −23.4%
Quarter to June 2026, against a year earlier
Follow ABEO
Alert me
Abeona Therapeutics Inc. (ABEO) EV/Sales
As of 6 November 2026, Abeona Therapeutics Inc. (ABEO) trades at a EV/Sales of 4.1×. Over the past ten years it has ranged from −16.1× (March 2020) to 858× (October 2017); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.5× | (41.17%) |
| FY2023 | 19.5× | — |
| FY2022 | −5.1× | — |
| FY2021 | −0.6× | — |
| FY2020 | 4.4× | (94.87%) |
| FY2018 | 86.2× | (87.61%) |
| FY2017 | 696× | 484.92% |
| FY2016 | 119× | 118.63% |
| FY2015 | 54.4× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.5× | 48.46% |
| Mar 2026 | 5.7× | (50.00%) |
| Dec 2025 | 11.5× | (38.09%) |
| Jun 2025 | 18.5× | 119.51% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | 0.4× |
| ABEO Abeona Therapeutics Inc. | 4.1× |
| ACIU AC Immune compare | 9.1× |
| FATE Fate Therapeutics, Inc. compare | 14.0× |
| KRRO Korro Bio, Inc. compare | 25.5× |
| IMRX Immuneering Corporation compare | 293× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)